Information contained on this page is provided by an independent third-party content provider. WorldNow and this Station make no warranties or representations in connection therewith. If you have any questions or comments about this page please contact email@example.com.
SOURCE AdvanDx, Inc.
WOBURN, Mass., May 16, 2014 /PRNewswire/ -- AdvanDx, Inc., a leading provider of molecular diagnostic tests for the rapid identification of bloodstream infections, announced today that data from thirteen studies will be presented at the 114th General Meeting for the American Society for Microbiology beginning on May 17 in Boston, Massachusetts.
Four of the studies will present data on mecA XpressFISH™ (FDA clearance pending), a novel method for the rapid detection of methicillin-resistant Staphylococcus aureus (MRSA) from positive blood cultures. AdvanDx recently submitted its mecA XpressFISH assay to the U.S. Food and Drug Administration for 510(k) clearance.
In addition, five studies will present data on the Company's QuickFISH products: Staphylococcus QuickFISH (FDA cleared; CE-IVD); Enterococcus QuickFISH (FDA cleared; CE-IVD); Gram-Negative QuickFISH (FDA cleared; CE-IVD); and QuickFISH Candida (CE-IVD).
"We're excited about the large number of studies being presented on our assays at the 2014 General Meeting of ASM, the world's largest meeting for microbiologists," says Dennis Langer, M.D., CEO of AdvanDx. "The studies highlight the accuracy, speed and reliability of our rapid diagnostics for the identification of life-threating bloodstream infections. We remain committed to our mission to develop innovative products that help clinicians improve patient outcomes and reduce overall healthcare costs."
The following posters will be presented at ASM:
AdvanDx, Inc. is a leading provider of advanced molecular diagnostic products for the prevention, diagnosis and treatment of life-threatening, bacterial infections. AdvanDx's easy-to-use products provide fast and accurate results that enable dramatic improvements in patient care and help to save lives and reduce hospital costs.
For more information visit www.AdvanDx.com.
©2012 PR Newswire. All Rights Reserved.